Search

Home > GRACEcast Lung Cancer Video > Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Podcast: GRACEcast Lung Cancer Video
Episode:

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
Category: Science & Medicine
Duration: 00:00:56
Publish Date: 2016-04-10 18:43:34
Description:

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Total Play: 0